Sign in
CompletedPhase 1/2

RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

Key facts

Who runs it
REGENXBIO Inc.
Where
Oakland, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
6 people enrolled
Started
11 Mar 2021
Ended
23 May 2024
Type of study
Interventional
Treatments tested
  • RGX-121
Record updated
28 January 2025

Who can take part

Age
5 years to 17 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Meets any of the following criteria:
  • Has a documented diagnosis of MPS II AND a neurocognitive testing score ≤ 1 ½ standard deviation (SD) from the test normative mean (BSID-III: 77 and MSEL Visual Reception: 35), OR
  • Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (BSID-III Cognitive or MSEL Visual Reception), OR
  • Has a relative clinically diagnosed with neuronopathic MPS II who has the same IDS mutation as the participant AND the participant in the opinion of a geneticist has inherited a neuronopathic form of MPS II, OR
  • Has documented mutation(s) in IDS that in the opinion of a geneticist is known to result in a neuronopathic phenotype AND in the opinion of a clinician has a neuronopathic form of MPS II

Who cannot take part

  • Has contraindications for immunosuppressive therapy
  • Has had prior treatment with an AAV-based gene therapy product
  • If receiving ELAPRASE® via intrathecal (IT) administration, must agree to discontinue IT idursulfase for the duration of the study
  • Is currently failing to respond to idursulfase (ELAPRASE®) IV due to neutralizing anti-idursulfase antibodies
  • Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing of the ICF, whichever is longer
  • Has any neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
  • Has experienced a serious hypersensitivity reaction to intravenous (IV) ELAPRASE®
  • Has a platelet count <100,000 per microliter (µL), absolute neutrophil count <1.0 × 103/µL, or aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at screening unless the participant has a previously known history of Gilbert's syndrome
  • Has contraindications for intracisternal injection, intracerebroventricular injection, or lumbar puncture

Where in United States

Also in 1 other country, 1 site

  • University of California San Francisco, Benioff Children's HospitalOakland, United States

About the trial

What the trial wants to find out

RGX-121 is a gene therapy which is designed to deliver a functional copy of the iduronate-2-sulfatase (IDS) gene to the central nervous system. This study is a phase I/II study to determine whether RGX-121 is safe, well tolerated, and potentially effective in children five years of age and over who have severe MPS II.

The group in the trial

  • Single ArmTreatment being tested

    6.5 × 10\^10 GC/g brain mass of RGX-121

    Treatment: RGX-121

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Children 5 Years of Age and Older With MPS II (Hunter Syndrome)
Record updated
28 January 2025